Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Galectin Therapeutics ( (GALT) ) is now available.
On January 23, 2025, Galectin Therapeutics presented significant findings from their NAVIGATE trial during their Annual Meeting of Stockholders. The trial, which concluded successfully in 2024, showed that their drug candidate, belapectin, demonstrated a favorable clinical effect in patients with MASH cirrhosis and portal hypertension. The results included a notable reduction in the incidence of new varices and positive outcomes in non-invasive biomarkers of fibrosis. These findings underscore the company’s commitment to addressing unmet medical needs and position Galectin as a potential leader in this area of treatment. The company plans to further engage with the FDA and potential partners to advance the development of belapectin.
More about Galectin Therapeutics
Galectin Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing therapies for diseases related to galectin proteins. Their primary product is belapectin, aimed at treating non-alcoholic steatohepatitis (MASH) cirrhosis with portal hypertension.
YTD Price Performance: 5.13%
Average Trading Volume: 733,780
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $76.64M
Learn more about GALT stock on TipRanks’ Stock Analysis page.
